cas 944401-77-8|| where to buy 2-Amino-4-fluoropyridine

Nom du produit:2-Amino-4-fluoropyridine

IUPAC Name:4-fluoropyridin-2-amine

Unité d'emballage	Stock disponible	Prix($)
CM120536-10g	in stock	ƋƱ
CM120536-25g	in stock	ƙƋǕ
CM120536-100g	in stock	ȷǧǧ
CM120536-500g	in stock	ƻƙǧǧ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 944401-77-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:944401-77-8; Formule moléculaire:C5H5FN2; Point de fusion:-; Code SMILES:FC1=CC(N)=NC=C1; Densité:

: Numéro de catalogue:CM120536; Poids moléculaire:112.11; Point d'ébullition:211.5°C at 760 mmHg; N° Mdl:MFCD09260906; Stockage:Keep in dark place, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: IDRX-42; IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.